VK-5211 is under clinical development by Viking Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect VK-5211’s likelihood of approval (LoA) and phase transition for Bone Fracture took place on 02 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VK-5211 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

VK-5211 overview

VK-5211 (LGD-4033) is under development for the treatment of acute hip fracture, muscle wasting and osteoporosis. The drug candidate is administered orally. VK5211 belongs to a family of non-steroidal selective androgen receptor modulator based on tissue-specific gene expression and other functional, cell-based technologies. The therapeutic candidate was also under development for treatment of cancer cachexia.

Viking Therapeutics overview

Viking Therapeutics is clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company lead clinical program product candidate include VK5211, an orally available, non-steroidal selective androgen receptor modulator developed for the treatment of lean body mass loss in patients who have undergone hip fracture surgery. Its other pipeline product candidates include VK0214 for the treatment of orphan indication, a rare X-linked inherited neurological disorder; VK2809 developed for orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease and VK0612, an inhibitor of fructose -1,6-biphosphatase for type 2 diabetes. Viking Therapeutics is headquartered in San Diego, California, the US.

Quick View VK-5211 LOA Data

Report Segments
  • Innovator
Drug Name
  • VK-5211
Administration Pathway
  • Oral
Therapeutic Areas
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.